scispace - formally typeset
Open AccessJournal ArticleDOI

A revised European-American classification of lymphoid neoplasms : a proposal from the international lymphoma study group

Reads0
Chats0
About
This article is published in Blood.The article was published on 1994-09-01 and is currently open access. It has received 6086 citations till now. The article focuses on the topics: Primary pulmonary lymphoma & MALT lymphoma.

read more

Citations
More filters
Journal ArticleDOI

Peripheral T-cell lymphoma: spectrum of imaging findings with clinical and pathologic features.

TL;DR: There is a correlation between specific clinicopathologic entities of PTCL and the primary site of involvement, although the findings in the disseminated stage of disease do not allow differential diagnosis.
Journal ArticleDOI

Immunolocalization of the ICE/Ced-3 - Family Protease, CPP32 (Caspase-3), in Non-Hodgkin's Lymphomas, Chronic Lymphocytic Leukemias, and Reactive Lymph Nodes

TL;DR: Analysis of normal lymph nodes, tonsils, and nodes affected with reactive hyperplasia showed strong immunoreactivity in the apoptosis-prone germinal center B-lymphocytes of secondary follicles, but little or no reactivity in the surrounding long-lived mantle zone lymphocytes, suggesting dynamic regulation of CPP32 expression in normal and malignant lymphocytes.
Journal ArticleDOI

Angiotropic Lymphoma: An Immunophenotypically and Clinically Heterogeneous Lymphoma

TL;DR: It is concluded that ALs are clinically and immunophenotypically heterogeneous and may represent more than one pathogenetic entity and some cases of AL may represent a transformation from another type of lymphoma.
Journal ArticleDOI

Clinical activity and safety of combination immunotherapy with IFN-alpha 2a and Rituximab in patients with relapsed low grade non-Hodgkin's lymphoma

TL;DR: Combination immunotherapy Rituximab + IFN- alpha 2a is active and relatively well tolerated, and the overall response rate of 70% and the median duration remission of 19 months compare favorable with the results obtained with RitUXimab alone in similar subset of patients.
Related Papers (5)